Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)
Industry: Healthcare

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Current Quote*
Last: $13.140
Change: -0.550
Book: $5.787
Volume: 169,616

As Of: 08/22 13:19 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol DRNA

  • No BuyIns.Net Alerts Available for DRNA

Graphs for DRNA


3 Month Graph


6 Month Graph


1 Year Graph